Literature DB >> 28132206

P025. Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real life evaluation of 113 patients.

Antonio Santoro1, Matteo Tanzi2, Anna Miscio3, Massimiliano Copetti2, Maurizio Leone3.   

Abstract

Entities:  

Year:  2015        PMID： 28132206      PMCID： PMC4715072          DOI： 10.1186/1129-2377-16-S1-A182

Source DB:  PubMed          Journal:  J Headache Pain        ISSN： 1129-2369            Impact factor:   7.277


× No keyword cloud information.
  2 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.

Authors:  Sheena K Aurora; Paul Winner; Marshall C Freeman; Egilius L Spierings; Jessica O Heiring; Ronald E DeGryse; Amanda M VanDenburgh; Marissa E Nolan; Catherine C Turkel
Journal:  Headache       Date:  2011-08-29       Impact factor: 5.887

2.  Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?

Authors:  Eva Cernuda-Morollón; César Ramón; Davinia Larrosa; Rocío Alvarez; Nuria Riesco; Julio Pascual
Journal:  Cephalalgia       Date:  2014-11-27       Impact factor: 6.292
  2 in total
  1 in total

Review 1.  Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations.

Authors:  Piero Barbanti; Patrizia Ferroni
Journal:  J Pain Res       Date:  2017-09-29       Impact factor: 3.133
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.